Redox status and protein binding of plasma aminothiols during the transient hyperhomocysteinemia that follows homocysteine administration.
We administered reduced L-homocysteine perorally (67 mumol/kg of body wt) to 12 healthy subjects and injected the same dose into one person, and determined the kinetics of the alterations in reduced, oxidized, and protein-bound concentrations of homocysteine, cysteine, and cysteinylglycine. After oral intake, reduced homocysteine increased rapidly (tmax < or = 15 min), reaching concentrations [3.97 (SD 2.99) mumol/L] 20-fold above fasting values, and then declined towards the normal concentration within 2 h. There was a similar increase in reduced cysteine and a moderate increase in reduced cysteinylglycine. During this response, we observed a positive correlation between the reduced/total ratio for homocysteine and cysteine. When homocysteine was injected, the increase in reduced homocysteine preceded the increase in reduced cysteine by about 3 min. After oral loading, oxidized homocysteine showed a transient increase (tmax = 30 min) that lagged behind the increase of reduced homocysteine. Oxidized cysteine and cysteinylglycine were stable or decreased slightly. Protein-bound homocysteine increased the least rapidly after homocysteine administration (tmax = 1-2 h), and returned to normal values slowly. Changes in protein-bound homocysteine essentially mirrored a concurrent decrease in protein-bound cysteine, suggesting displacement of bound cysteine. These data show that plasma homocysteine has a pronounced, direct effect on the redox status and protein binding of other plasma thiol components. Such effects should be recognized when studying the mechanisms behind the atherogenic effect of increased plasma homocysteine.
Department of Pharmacology and Toxicology, University of Bergen, Haukeland Hospital, Norway.
M A
MA
Mansoor
A B
AB
Guttormsen
T
T
Fiskerstrand
H
H
Refsum
P M
PM
Ueland
A M
AM
Svardal
D000328:Adult; D001798:Blood Proteins / Q000378:metabolism*; D003545:Cysteine / Q000097:blood; D004151:Dipeptides / Q000097:blood; D005260:Female; D006710:Homocysteine / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D006801:Humans; D007700:Kinetics; D008297:Male; D010084:Oxidation-Reduction; D011485:Protein Binding; D012044:Regression Analysis; D013438:Sulfhydryl Compounds / Q000097:blood*
D001798:Blood Proteins; D004151:Dipeptides; D013438:Sulfhydryl Compounds; D006710:Homocysteine; C028505:cysteinylglycine; D003545:Cysteine